BIOMEA FUSION INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About BMEA
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Find out what a historical investment in BIOMEA FUSION INC would be worth today using our BMEA stock calculator.
$66.50M
-
0.00%
744.29K
$1.82
$1.63
$1.76
$13.43
$1.53
Ready to start your investing journey with Stake?
Open an accountBMEA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in BMEA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in BMEA
on Stake
Buy BMEA from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of BMEA from only US$10 with fractional shares
